Mersana Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results
May 09, 2023 07:00 ET
|
Mersana Therapeutics, Inc.
Initiated dose expansion portion of UPGRADE-A clinical trial of UpRi in combination with carboplatin; interim data expected in second half of 2023Advanced enrollment in Phase 3 UP-NEXT clinical trial...
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 04, 2023 16:05 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference
May 03, 2023 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics to Host First Quarter 2023 Conference Call on May 9, 2023
May 02, 2023 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Upcoming Presentations at 2023 ASCO Annual Meeting
April 26, 2023 16:05 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 06, 2023 16:05 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., April 06, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Clinical Hold on XMT-2056 Phase 1 Clinical Trial
March 13, 2023 07:30 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., March 13, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Provides Statement About SVB
March 10, 2023 19:10 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., March 10, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 03, 2023 16:05 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., March 03, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2022 Financial Results
February 28, 2023 07:00 ET
|
Mersana Therapeutics, Inc.
Commenced dose expansion portion of Phase 1 UPGRADE-A clinical trial of UpRi in combination with carboplatinInitiated patient dosing in Phase 1 clinical trial of lead Immunosynthen ADC candidate,...